[go: up one dir, main page]

WO2009003010A3 - Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane, et articles médicaux enrobés d'organopolysiloxane contenant une solution de protéines - Google Patents

Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane, et articles médicaux enrobés d'organopolysiloxane contenant une solution de protéines Download PDF

Info

Publication number
WO2009003010A3
WO2009003010A3 PCT/US2008/068136 US2008068136W WO2009003010A3 WO 2009003010 A3 WO2009003010 A3 WO 2009003010A3 US 2008068136 W US2008068136 W US 2008068136W WO 2009003010 A3 WO2009003010 A3 WO 2009003010A3
Authority
WO
WIPO (PCT)
Prior art keywords
organopolysiloxane
protein
aggregation
evaluating
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/068136
Other languages
English (en)
Other versions
WO2009003010A2 (fr
Inventor
John Frank Carpenter
Theodore Randolph
John Paul Gabrielson
Jean-Bernard Hamel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Becton Dickinson and Co
University of Colorado Denver
University of Colorado Anschutz Medical Campus
Original Assignee
Becton Dickinson and Co
University of Colorado Denver
University of Colorado Anschutz Medical Campus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson and Co, University of Colorado Denver, University of Colorado Anschutz Medical Campus filed Critical Becton Dickinson and Co
Priority to CN200880119613XA priority Critical patent/CN101889209A/zh
Priority to JP2010531196A priority patent/JP5081976B2/ja
Priority to PCT/US2008/080721 priority patent/WO2009055427A2/fr
Priority to US12/739,009 priority patent/US8633034B2/en
Priority to EP20100164045 priority patent/EP2237038B1/fr
Priority to ES10164045.6T priority patent/ES2543735T3/es
Priority to EP08841038.6A priority patent/EP2201380B1/fr
Priority to CN201610529593.XA priority patent/CN106443002A/zh
Publication of WO2009003010A2 publication Critical patent/WO2009003010A2/fr
Publication of WO2009003010A3 publication Critical patent/WO2009003010A3/fr
Anticipated expiration legal-status Critical
Priority to JP2012154844A priority patent/JP5978034B2/ja
Priority to US14/139,604 priority patent/US20140110297A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/82—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a precipitate or turbidity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N2015/0092—Monitoring flocculation or agglomeration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Plasma & Fusion (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés permettant d'évaluer ou d'inhiber l'agrégation d'une protéine dans une suspension aqueuse incluant un organopolysiloxane, et des articles médicaux enrobés d'un organopolysiloxane contenant une solution de protéines qui comprend un sucre et un tensioactif non ionique.
PCT/US2008/068136 2007-06-25 2008-06-25 Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane, et articles médicaux enrobés d'organopolysiloxane contenant une solution de protéines Ceased WO2009003010A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ES10164045.6T ES2543735T3 (es) 2007-10-22 2008-10-22 Artículos médicos revestidos con organopolisiloxano que contienen una disolución de proteína y un tensioactivo no iónico
CN201610529593.XA CN106443002A (zh) 2007-10-22 2008-10-22 评价在含有机基聚硅氧烷的悬浮液中蛋白质聚集的方法
PCT/US2008/080721 WO2009055427A2 (fr) 2007-10-22 2008-10-22 Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane et articles médicaux recouverts d'un organopolysiloxane contenant une solution protéique
US12/739,009 US8633034B2 (en) 2007-06-25 2008-10-22 Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
EP20100164045 EP2237038B1 (fr) 2007-10-22 2008-10-22 Articles médicaux revêtus d'organopolysiloxane contenant une solution de protéine et tensioactif non ionique
CN200880119613XA CN101889209A (zh) 2007-10-22 2008-10-22 评价在含有机基聚硅氧烷的悬浮液中蛋白质聚集的方法和用含蛋白质溶液的有机基聚硅氧烷涂布的医疗制品
EP08841038.6A EP2201380B1 (fr) 2007-10-22 2008-10-22 Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane et articles médicaux recouverts d'un organopolysiloxane contenant une solution protéique
JP2010531196A JP5081976B2 (ja) 2007-10-22 2008-10-22 オルガノポリシロキサンを含む懸濁液においてタンパク質の凝集を評価するための方法
JP2012154844A JP5978034B2 (ja) 2007-10-22 2012-07-10 オルガノポリシロキサンを含む懸濁液においてタンパク質の凝集を評価するための方法、およびタンパク質溶液を含有する、オルガノポリシロキサンでコーティングされた医療用品
US14/139,604 US20140110297A1 (en) 2007-06-25 2013-12-23 "Medical Articles Coated With Organopolysiloxane Containing a Protein Solution"

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93717907P 2007-06-25 2007-06-25
US60/937,179 2007-06-25

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2008/080721 Continuation-In-Part WO2009055427A2 (fr) 2007-06-25 2008-10-22 Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane et articles médicaux recouverts d'un organopolysiloxane contenant une solution protéique
US12/739,009 Division US8633034B2 (en) 2007-06-25 2008-10-22 Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
US12/739,009 Continuation-In-Part US8633034B2 (en) 2007-06-25 2008-10-22 Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution

Publications (2)

Publication Number Publication Date
WO2009003010A2 WO2009003010A2 (fr) 2008-12-31
WO2009003010A3 true WO2009003010A3 (fr) 2009-02-12

Family

ID=40186268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/068136 Ceased WO2009003010A2 (fr) 2007-06-25 2008-06-25 Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane, et articles médicaux enrobés d'organopolysiloxane contenant une solution de protéines

Country Status (1)

Country Link
WO (1) WO2009003010A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2201380B1 (fr) 2007-10-22 2016-06-01 Becton Dickinson and Company Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane et articles médicaux recouverts d'un organopolysiloxane contenant une solution protéique
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
JP6798993B2 (ja) 2014-12-23 2020-12-09 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素プレフィルド容器
KR102627068B1 (ko) * 2015-02-03 2024-01-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소 사전충전된 용기
ES2797298T3 (es) 2016-02-10 2020-12-01 Becton Dickinson France Procedimiento para evaluar la estabilidad de una formulación a base de proteína

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525084B2 (en) * 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6638519B1 (en) * 1999-11-08 2003-10-28 L'oreal Composition for topical application comprising a sugar and its cosmetic uses
US20050053598A1 (en) * 2003-02-10 2005-03-10 Burke David J. Immunoglobulin formulation and method of preparation thereof
US20050123947A1 (en) * 1997-09-23 2005-06-09 California Institute Of Technology Methods and systems for molecular fingerprinting
US20060051353A1 (en) * 2004-05-14 2006-03-09 Jean-Frederic Colombel Methods and compositions to evaluate antibody treatment response

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123947A1 (en) * 1997-09-23 2005-06-09 California Institute Of Technology Methods and systems for molecular fingerprinting
US6525084B2 (en) * 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
US6638519B1 (en) * 1999-11-08 2003-10-28 L'oreal Composition for topical application comprising a sugar and its cosmetic uses
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20050053598A1 (en) * 2003-02-10 2005-03-10 Burke David J. Immunoglobulin formulation and method of preparation thereof
US20060051353A1 (en) * 2004-05-14 2006-03-09 Jean-Frederic Colombel Methods and compositions to evaluate antibody treatment response

Also Published As

Publication number Publication date
WO2009003010A2 (fr) 2008-12-31

Similar Documents

Publication Publication Date Title
WO2009055427A3 (fr) Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane et articles médicaux recouverts d'un organopolysiloxane contenant une solution protéique
WO2009158015A3 (fr) Antagonistes d’actriib et utilisations pour augmenter les taux d’érythrocytes
IL183249A0 (en) Packaging articles, films and methods that promote or preserve the desirable color of meat
WO2008076437A3 (fr) Antagonistes de l'activine-actrii et ses utilisations pour accroître les niveaux de globules rouges
ME02268B (fr) Processus de préparation d'électrodes modifiées, électrodes préparées avec ce processus, et biocapteurs enzymatiques comportant ces électrodes
EP2253227A4 (fr) Agent de renforcement de salinité et aliment ou boisson le contenant
IL195645A0 (en) Pullulan film, edible articles incorporating the same and methods for making the same
EP2263477A4 (fr) Agent de renforcement de goût salé et aliment ou boisson le contenant
EP2447274A3 (fr) Composants oligomères et procédés
WO2007109221A3 (fr) Methodes de reduction de l'agregation des proteines
WO2007126824A3 (fr) Procédés et systèmes de stérilisation
EP2789246A4 (fr) Agent améliorant le goût et aliment ou boisson le contenant
WO2010066012A3 (fr) Nutriment contenant des arabinoxylanes et des oligosaccharides
CL2014001100A1 (es) Formulacion enzimatica liquida que comprende por lo menos una enzima para el entrecruzamiento y/o modificacion de proteinas lacteas en suspension de poliol-agua que contiene desde 25 a 100% (p/p) de poliol y que tiene un valor de ph dentro de la escala de 4,4 a 5,1; y metodo para preparar la formulacion.
WO2007019176A3 (fr) Concentres de proteines de mais
WO2009114475A3 (fr) Compositions comprenant de la pcsk9 humaine et un siarn d’apolipoprotéine b, et procédés d’utilisation de celles-ci
EP2062861A4 (fr) Préproduction dépourvue de condensation, articles dépourvus de condensation et fluide de revêtement pour les articles
IL215592A (en) Compounds, preparations containing them and their uses in the treatment or prevention of conditions in the eyes
ZA200806998B (en) Agent enriched nanoparticles based on hydrophilic proteins
WO2008033520A3 (fr) Séquences géniques de bifidobactéries et leur utilisation
EP2335665A4 (fr) Article de gestion liquidienne et article vestimentaire le comprenant
WO2009003010A3 (fr) Procédés d'évaluation de l'agrégation d'une protéine dans une suspension comprenant un organopolysiloxane, et articles médicaux enrobés d'organopolysiloxane contenant une solution de protéines
EP2245091A4 (fr) Dispersion de nanoparticules, compositions la contenant et articles obtenus à partir de celles-ci
EP2011498A4 (fr) Agent ameliorant les fonctions cerebrales et aliment fonctionnel contenant l'agent ameliorant
WO2008040872A3 (fr) Utilisation de la gomme arabique pour ameliorer la croissance et la survie des bifidobacteries.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08771891

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08771891

Country of ref document: EP

Kind code of ref document: A2